Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Weidong Ma
Institutions:
Tianjin Medical University Cancer Institute and Hospital,
Tianjin Medical University
Observed institutions:
Tianjin Medical University Cancer Institute and Hospital,
Tianjin Medical University
ORCID:
0009-0001-8561-6108
Observed ORCID:
0009-0001-8561-6108
OpenAlex ID:
A5122787350
Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
2025
·
Xiuchao Wang
, Hongwei Wang
, et al.
·
Cancer Discovery
·
9
Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study
2023
·
Haorui Li
, Yu Guo
, et al.
·
Frontiers in Oncology
·
2
PDF
NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial
2026
·
Chuntao Gao
, Yanqiao Zhang
, et al.
·
Nature Communications
·
1
PDF
Supplementary Text 1 from Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
2026
·
Xiuchao Wang
, Hongwei Wang
, et al.
·
1
Supplementary Figures S1-S13 from Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
2026
·
Xiuchao Wang
, Hongwei Wang
, et al.
PDF
Data from Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
2026
·
Xiuchao Wang
, Hongwei Wang
, et al.
Supplementary Tables S1-S8 from Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
2026
·
Xiuchao Wang
, Hongwei Wang
, et al.
Show more works
View as search
Works count:
7
Citation count:
13
H-index:
2
I10-index:
Year
Topic
Type